Who
Joseph Oliveto
President and CEO
Company insider
Files Form 4 as: President and CEO, Milestone Pharmaceuticals; President and CEO, Chelsea Therapeutics International.
In numbers
- Trades disclosed
- 62
- Buys
- 1
- Sells
- 5
- Bought
- $10K
- Sold
- $1.1M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 13 Jun 2008
- Last trade
- 16 Apr 2026
- Last filed
- 20 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Apr 2026filed 20 Apr 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $82K36,500 at $2.26 | filing |
| 16 Apr 2026filed 20 Apr 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $82K36,500 at $2.26 | filing |
| 2 Feb 2026filed 5 Feb 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —679,000 at $0.00 | filing |
| 2 Feb 2026filed 5 Feb 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —679,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —679,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —453,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —679,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —453,000 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —66,600 | filing |
| 26 Jan 2026filed 28 Jan 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —66,600 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $67K34,523 at $1.93 | filing |
| 26 Jan 2026filed 28 Jan 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —66,600 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —66,600 | filing |
| 26 Jan 2026filed 28 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $67K34,523 at $1.93 | filing |
| 8 Jan 2026filed 9 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $97K43,000 at $2.25 | filing |
| 8 Jan 2026filed 9 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $97K43,000 at $2.25 | filing |
| 7 Jan 2026filed 9 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1,125500 at $2.25 | filing |
| 7 Jan 2026filed 9 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1,125500 at $2.25 | filing |
| 15 Dec 2025filed 28 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $309K133,054 at $2.32 | filing |
| 15 Dec 2025filed 28 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $309K133,054 at $2.32 | filing |
News
Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology ConferencesMIST · manilatimes.net · 19 Oct 2026Head-To-Head Analysis: Milestone Pharmaceuticals (NASDAQ:MIST) & Bristol Myers Squibb (NYSE:BMY)MIST · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Joseph Oliveto; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.